Jeune Syndrome Market

Market Overview:

The 7 major jeune syndrome markets reached a value of USD 467.8 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 764.4 Million by ​2035​, exhibiting a growth rate (CAGR) of 4.57% during 2025-2035. 

The jeune syndrome market has been comprehensively analyzed in IMARC's new report titled "Jeune Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Jeune syndrome, or asphyxiating thoracic dystrophy, is an uncommon genetic disease described by a bell-shaped, narrow chest, causing distress in breathing in affected newborns. Jeune syndrome occurs due to mutations of genes involved in ciliary function that affect both skeletal growth and organ function. Signs differ in severity but typically involve respiratory insufficiency, short ribs, polydactyly, renal abnormalities, and growth retardation. In advanced cases, respiratory complications may be fatal in infancy. Diagnosis of Jeune syndrome is usually through clinical assessment, genetic analysis, and imaging. Radiographic evaluation, such as X-rays and CT scans, identifies typical skeletal deformities, while genetic analysis can establish mutations in genes like IFT80, DYNC2H1, and WDR19. Prompt diagnosis is essential to control complications, especially respiratory distress, that could necessitate ventilatory assistance or surgical intervention like thoracic expansion operations.

The increasing level of awareness towards rare genetic diseases and improvements in genetic testing are the major driving forces for the Jeune syndrome market. Since healthcare systems place greater emphasis on the early identification of congenital diseases, heightened newborn screening programs and genetic counseling schemes are greatly contributing to detecting Jeune syndrome at an early stage. Moreover, the increasing availability of next-generation sequencing (NGS) and whole-exome sequencing has greatly enhanced diagnostic accuracy, allowing the determination of causative genetic mutations like IFT80, DYNC2H1, and WDR19. This is, in turn, aiding in the development of personalized treatment modalities depending on the severity of the condition. In addition, increasing research on ciliopathies and skeletal dysplasias is precipitating potential therapies in the forms of gene therapy and pharmacologically directed interventions, the aim being to alter the course of disease. Supportive treatment modalities like ventilatory assistance and corrective surgical procedures in the form of thoracic expansion procedures are similarly enhancing survival. Also, partnerships among rare disease patient organizations, research organizations, and pharmaceutical firms are promoting clinical trials and funding, which are likely to fuel additional innovations in Jeune syndrome treatment during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the jeune syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the jeune syndrome market in any manner.

Recent Developments:

• In October 2024, the Symani Surgical System was recognized as a top invention, offering advanced microsurgical capabilities that could benefit complex procedures related to Jeune syndrome.
• In November 2023, a non-invasive prenatal test (desNIPT) was developed for early detection of Jeune syndrome using fetal DNA from maternal blood, eliminating the need for invasive diagnostic procedures.
• In May 2023, a minimally invasive progressive internal distraction of the sternum (PIDS) method was developed to gradually expand the thoracic cavity, enhancing pulmonary development in Jeune syndrome patients.

Key Highlights:

• Jeune syndrome is a rare genetic disorder affecting approximately 1 in 100,000 to 130,000 live births, primarily causing skeletal abnormalities and respiratory distress.
• It follows an autosomal recessive inheritance, with mutations in genes like WDR34, WDR60, and IFT172 linked to its development.
• Symptoms include a narrow chest, short ribs, polydactyly, short stature, and respiratory distress due to thoracic insufficiency.
• Patients may develop kidney abnormalities, liver disease, pancreatic cysts, dental anomalies, and retinal dystrophy, potentially causing vision impairment.
• Diagnosis involves imaging and genetic testing, while treatment focuses on respiratory support and surgeries like VEPTR to expand the chest cavity.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the jeune syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the jeune syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current jeune syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the jeune syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the jeune syndrome market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the jeune syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​​2019-2035​​) of jeune syndrome across the seven major markets?
• What is the number of prevalent cases (​​2019-2035​​) of jeune syndrome by age across the seven major markets?
• What is the number of prevalent cases (​​2019-2035​​) of jeune syndrome by gender across the seven major markets?
• How many patients are diagnosed (​​2019-2035​​) with jeune syndrome across the seven major markets?
• What is the size of the jeune syndrome patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of jeune syndrome?
• What will be the growth rate of patients across the seven major markets?

Jeune Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for jeune syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the jeune syndrome market?
• What are the key regulatory events related to the jeune syndrome market?
• What is the structure of clinical trial landscape by status related to the jeune syndrome market?
• What is the structure of clinical trial landscape by phase related to the jeune syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the jeune syndrome market?